Neuro-Psychiatric disorders: Anxiety, psychosis, BPD, mood disorders

• Anxiety
• Psychosis
• Bipolar disorder
• Depression
• Panic attacks
• PTSD (Post-traumatic stress disorder)
• Social Anxiety disorder
• OCD (Obsessive compulsive disorder)
• Seizures
• Eating disorders
• ADHD
• Migraine headaches

There are wide range of treatments currently available for neuro-psychiatric disorders but most of them are associated with limited response, adverse side-effect profile, and residual symptoms. In various animal models, activation of CB1 receptors has shown to be reduce anxiety, panic, compulsion, fear-conditioned response (fear extinction), and reduce consolidation of negative memories.

CBD has been highly studied in the context of public speaking. Studies have shown that CBD not only reduced anxiety associated with public speaking but it also reduced anticipatory anxiety in both healthy individuals and those suffering from SAD (Social Anxiety disorder).

Human studies have also shown that CBD is protective against the psychotic effects of THC in higher doses especially in long-term users.

Another study concluded that phyto-cannabinoids and terpenes in cannabis were associated with reduction in ADHD medications. A particular cannabinoid called CBN was associated with reduction in ASRS scores (that are used to evaluated ADHD in adults).

Reference:

Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 1982;76:245–250. doi: 10.1007/BF00432554.

Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol. 1993;7:82–88.
Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011;36:1219–1226. doi: 10.1038/npp.2011.6

Cannabidiol as a potential treatment for Anxiety disorders. Neurotherapeutics. 2015 Oct; 12(4): 825–836. Published online 2015 Sep 4. doi: 10.1007/s13311-015-0387-1
Use of cannabidiol in anxiety and anxiety-related disorders. Jessica W Skelley et al. J Am Pharm Assoc (2003). Jan-Feb 2020;60(1):253-261. doi: 10.1016/j.japh.2019.11.008.

Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders. Maria S et al. Biomolecules. 2020 Nov; 10(11): 1575. Published online 2020 Nov 19. doi: 10.3390/biom10111575

Cannabinoid and Terpenoid Doses are Associated with Adult ADHD Status of Medical Cannabis Patients. Jeffrey Y et al. Rambam Maimonides Med J. 2020 Jan; 11(1): e0001.